Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Corrected, then climbed again, that's this particular market's late 2025 into the year 2026. The United States carries the highest cost of all the tracked markets, up by 3.3% in the first half of 2026 (H1 2026), from a value of USD 186/KG from USD 180/KG in Q1. The import tariffs on Chinese pharmaceutical supplies are the reason the US sits where it does. The steady anticonvulsant formulation demand added to the recovery further. Globally the average moved from a value of USD 160.2/KG to USD 165.6/KG, a gain of 3.4 percent. For the second half of 2026 (H2 2026), a range of USD 165-182/KG looks reasonable. That assumes the Oxcarbazepine and Eslicarbazepine acetate manufacturing demand stays on its current track.
10-Methoxy Iminostilbene carries a methoxy group at the 10-position on a tricyclic iminostilbene core, produced through a multi-step organic synthesis. Its job is specific and somewhat unforgiving in nature. It serves as the penultimate intermediate in the commercial Oxcarbazepine manufacturing routes. The upstream quality here directly impacts the purity and safety of the final API. That's why the stringent controls on related substances and residual solvents matter so much throughout the production. The Oxcarbazepine synthesis absorbs the overwhelming majority of the demand, feeding into this widely prescribed anticonvulsant used for epilepsy and seizure disorders. The Eslicarbazepine acetate production takes a smaller slice of it. A limited personal care application draws on its antioxidant properties too. The multi-step synthesis and purification costs set the baseline. The import tariffs and freight conditions add on top of that. The neurology-sector demand cycles shape whatever's left.
A real upward momentum, that's how the market entered the second half of 2026 (H2 2026), after what was, honestly, a choppy year 2025. The Oxcarbazepine and Eslicarbazepine acetate manufacturers restocked steadily through the H1, tracking the production needs in the neurology space fairly closely. The import tariffs on Chinese pharmaceutical supplies kept the US landed costs elevated even as the Trans-Pacific freight rates eased somewhat. That's why the production floor firmed instead of dropping.
Further tariff tightening, or a supply disruption at a major Chinese or Indian facility, could push the prices above the band. A tariff reversal, or a softer anticonvulsant demand, would work the other way around.
| Region | 2026 Price Range (USD/KG) | Outlook |
| Global Average | 165 - 182 | Anticonvulsant demand and tariff cost support |
| United States | 182 - 200 | Import tariffs maintain the highest premium |
| China | 148 - 163 | Primary export capacity keeps China most affordable |
| Germany | 173 - 190 | Compliance standards support firm pricing |
| India | 156 - 172 | Growing manufacturing capacity supports firm middle |
The US prices climbed by 3.3% to a value of USD 186/KG. The import tariffs on Chinese pharmaceutical supplies kept the landed costs elevated. The steady neurology-sector demand meant there wasn't much slack to absorb the tariff impact.
Why did the price of 10-Methoxy Iminostilbene change in Q2 2026 in the United States?
Import tariffs on Chinese pharmaceutical supplies kept landed costs elevated all quarter. Steady demand from Oxcarbazepine and Eslicarbazepine acetate manufacturers supported buying regardless. Trans-Pacific freight rates eased only modestly, so there wasn't much cost relief to offset the tariff pressure.
China rose by 3.4% to a value of USD 152/KG, still the cheapest tracked market by a comfortable margin. The steady manufacturing output continued as before. A firmer export demand from pharmaceutical formulators pushed the market up modestly.
Why did the price of 10-Methoxy Iminostilbene change in Q2 2026 in China?
Steady manufacturing output at Chinese facilities kept supply consistent through the quarter. Firmer export demand from Oxcarbazepine formulators lifted procurement. Feedstocks stayed available without disruption, keeping the increase measured rather than sharp.
Germany led every single tracked market at a value of USD 177/KG, up by 3.5%. The strict compliance standards for pharmaceutical intermediates are the recurring theme here. They keep the European costs elevated regardless of what's happening elsewhere.
Why did the price of 10-Methoxy Iminostilbene change in Q2 2026 in Germany?
Strict European compliance standards for pharmaceutical intermediates kept production costs elevated. Steady anticonvulsant formulation demand supported buying throughout the quarter. USD 177/KG is where things landed.
India climbed by 3.2% to a value of USD 159/KG. A growing domestic manufacturing capacity and a firm anticonvulsant demand supported the increase. A fairly clean two-factor story for this particular market.
Why did the price of 10-Methoxy Iminostilbene change in Q2 2026 in India?
Growing domestic manufacturing capacity for Oxcarbazepine intermediates sustained firm demand. Feedstock costs firmed modestly in line with broader input inflation. Export demand added a bit more support near USD 159/KG.
The US prices rose by 2.3% to a value of USD 180/KG in Q1, recovering from the late-2025 softness. The Chinese and Indian manufacturers kept churning out normal volumes. An improving restocking sentiment did the rest.
Why did the price of 10-Methoxy Iminostilbene change in Q1 2026 in the United States?
Chinese and Indian manufacturers maintained normal production volumes without any real disruption. Improving restocking sentiment among US distributors lifted procurement steadily. The 25 percent import tax on Chinese pharmaceutical supplies kept landed costs elevated throughout.
China's Q1 average rose by 2.1% to a value of USD 147/KG, a modest recovery from the late-2025 correction. Steady production. Steady feedstock availability. A fairly unremarkable quarter overall.
Why did the price of 10-Methoxy Iminostilbene change in Q1 2026 in China?
Steady production levels and readily available feedstocks supported consistent output. An improving pharmaceutical demand outlook lifted procurement modestly. USD 147/KG is where the market recovered to.
Germany rose by 2.4% to a value of USD 171/KG in Q1, supported by the steady anticonvulsant formulation demand, the same recurring driver that would carry through into the stronger Q2 gain.
Why did the price of 10-Methoxy Iminostilbene change in Q1 2026 in Germany?
Steady anticonvulsant formulation demand supported consistent buying through the quarter. Compliance-related costs held firm without adding much extra pressure. The market recovered to USD 171/KG.
India rose by 2.0% to a value of USD 154/KG in Q1. The growing manufacturing capacity and the firm demand supported the increase, setting up the further gain that followed in the Q2.
Why did the price of 10-Methoxy Iminostilbene change in Q1 2026 in India?
Growing domestic manufacturing capacity supported steady procurement through the quarter. Firm anticonvulsant formulation demand lifted buying alongside it. USD 154/KG is where the quarter closed.
This one genuinely swung both directions across the entire six-quarter window, unlike most of the markets we track. The prices rose through mid-2025, corrected through the back half of the year, then recovered into the year 2026. From a value of USD 157.9/KG in Q1 2025 to USD 165.6/KG by Q2 2026, a net gain of 4.9 percent that understates just how much back-and-forth happened in between. The inventory cycles and the shifting import tariff conditions explain most of the mixed pattern.
| Quarter | Price (USD/KG) | QoQ Change | Direction |
| Q2 2026 | 165.6 | +3.4% | ↑ Rising |
| Q1 2026 | 160.2 | +2.2% | ↑ Rising |
| Q4 2025 | 156.8 | -1.4% | ↓ Falling |
| Q3 2025 | 159.0 | -1.4% | ↓ Falling |
| Q2 2025 | 161.2 | +2.1% | ↑ Rising |
| Q1 2025 | 157.9 | - | - Stable |
A mixed year, that's the year 2025 here, rising into mid-year before correcting into the year-end. The global average opened at a value of USD 157.9/KG in Q1, eased to USD 156.8/KG by Q4, essentially flat at a decline of 0.7 percent. The post-holiday inventory overbuilds in early 2025 introduced real instability into the market. The rising import costs and improving restocking sentiment provided periodic upward pressure that never quite offset the corrections.
The US prices eased slightly, from a value of USD 178/KG to USD 176/KG, a decline of 1.1 percent. The soft freight and stable supply from Asian manufacturers kept the market contained even with the tariff pressures in the background.
The Chinese prices ended essentially where they started, from a value of USD 145/KG to USD 144/KG, flat for the entire year. The steady production, along with the feedstock availability, kept the market well supplied throughout the year.
The German prices eased slightly, from a value of USD 168/KG to USD 167/KG, a decline of 0.6 percent. The steady anticonvulsant demand kept the market largely stable across the year.
The Indian prices eased slightly too, from a value of USD 152/KG to USD 151/KG, a decline of 0.7 percent. A growing manufacturing capacity kept the market broadly stable throughout the year.
Expert Market Research: Your Source for Real-Time 10-Methoxy Iminostilbene Price Intelligence
Expert Market Research tracks the 10-Methoxy Iminostilbene prices continuously, across every major producing and consuming region. The team traces the causation through the multi-step synthesis and purification economics, the import tariff and freight cost cycles, and the shifting Oxcarbazepine and Eslicarbazepine acetate manufacturing demand. Contact Expert Market Research today for the 10-Methoxy Iminostilbene pricing data, a bespoke market analysis, and a strategic procurement advisory.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
The Oxcarbazepine synthesis takes the overwhelming majority of the demand, serving as the penultimate intermediate in the commercial manufacturing routes for this widely prescribed anticonvulsant. The Eslicarbazepine acetate production and a limited personal care application draw modest volumes too.
The Q2 2026 prices come to a value of USD 186/KG in the United States, USD 152/KG in China, USD 177/KG in Germany, and USD 159/KG in India. The import tariffs on Chinese pharmaceutical supplies explain why the United States sits well above the other three.
The global average rose from a value of USD 156.8/KG in Q4 2025 to USD 160.2/KG in Q1 2026, then to USD 165.6/KG by Q2, a gain of 3.4 percent across the half-year. The improving restocking sentiment, along with the steady anticonvulsant demand, drove the recovery.
The post-holiday inventory overbuilds from early 2025 introduced a genuine instability into the pricing. The subdued summer demand contributed to a quarter-over-quarter decline in North America specifically. The Chinese and Indian manufacturers kept production running normally throughout, so supply itself was never really the issue here.
A range of USD 165 to 182/KG looks like the right one for the rest of the year 2026, assuming the Oxcarbazepine and Eslicarbazepine acetate manufacturing demand holds and the import tariffs stay in place.
The United States carries the highest cost, owing to the import tariffs affecting the Chinese pharmaceutical supplies specifically. Germany holds a premium tied to the compliance standards. India sits in the middle, owing to the growing manufacturing capacity. China prices the lowest, as the primary global exporter.
Monthly. Reach out to the Expert Market Research team directly for real-time pricing intelligence.
The multi-step synthesis and purification costs sit at the core of it, with the import tariffs and freight rates along the major trade routes close behind. The currency fluctuations and inventory cycles matter too, and the neurology-sector demand for anticonvulsant medications shapes how the downstream procurement plays out.
China acts as the primary global exporter, with India following as a significant manufacturing hub. The United States and Europe function mainly as import-driven consumption regions for this particular specialty pharmaceutical intermediate.
Timing the Oxcarbazepine manufacturing contracts around the anticipated tariff and freight cost changes is the main lever here. The import tariff conditions give the clearest signal for the near-term direction, mattering more here than for most other intermediates given the compound's direct exposure to the cross-border trade policy.
One Year Subscription
One Year Subscription
USD 799
USD 699
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.